Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-05-08
2001-07-03
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S133000
Reexamination Certificate
active
06255320
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention is directed to an anhydrous (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo[2,2,2] octan-3-amine citrate monohydrate salt, its single crystalline polymorphic Form A, and pharmaceutical composition containing them. The invention is also directed to a CNS active NK-1 receptor antagonist for treating emesis in a mammal including humans. Treating is defined here as preventing and treating.
U.S. Pat. No. 5,393,762 and U.S. Ser. No. 08/816,016, both incorporated by reference, describe pharmaceutical compositions and treatment of emesis using NK-1 receptor antagonists. The citrate monohydrate has significantly enhanced stability over other salt forms such as the benzoate which was unstable even at 5° C. The mesylate form is deliquescent.
SUMMARY OF THE INVENTION
The present invention relates to the citrate monohydrate of (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo[2,2,2]octan-3-amine. In one embodiment of the invention, the citrate monohydrate is a crystalline stable nonhygroscopic single form. The crystalline habits are plates and are characterized by the x-ray powder detraction pattern given below:
Citrate Monohydrate
Peak No.
1
2
3
4
5
6
7
d space
13.28
7.70
7.45
6.34
5.33
5.06
4.40
The crystalline citrate monohydrate salt is nonhygroscopic, and is characterized by loss of water (volatilization) at about 116° C. and a melt onset of at about 152.7° C. The anhydrous citrate was converted to the monohydrate in water.
A pharmaceutical composition having CNS active NK-1 receptor antagonist activity comprises the polymorphic Form A in an amount effective in the treatment of emesis, and a pharmaceutically acceptable carrier. A method of treating emesis comprises administering to a subject in need of treatment an emetic effective amount of the polymorphic form of the compound.
A method of making the polymorphic Form A of (2S,3S)-N-(methoxy-5-t-butylphenylmethyl-2-diphenylmethyl-1-azobicyclo 2,2,2 octan-3-amine citrate monohydrate salt comprises adding citric acid to a solution of the free base in acetone. The solid was dissolved for about two hours. The clear solution was filtered and stirred overnight. Filtered isopropyl ether was added followed by the addition of filtered water. The resulting mixture was stirred at ambient termperature until crystallization started and granulated for about 16 hours. The white crystalline form was collected by filtration and dried at about 45° C. under vacuum with a nitrogen purge for about 24 hours.
DETAILED DESCRIPTION OF THE INVENTION
A method of making crystalline citrate monohydrate, polymorphic Form A comprises the addition of 353.9 gm, 1.1 equivalents of citric acid (anhydrous, 99.5+%) to a solution of the free base, 785 gm in acetone, 7.85 liters. After dissolution of the solid for about 2 hours, clear solution was filtered, stirred overnight and filtered isopropyl ether, 7.85 liters was added followed by the addition of filtered water, 334 mls. The resulting mixture was stirred at ambient temperature until crystallization started and granulated for an additional 16 hours. The white crystalline salt formed was collected by filtration and dried at 45° C. under vacuum with a nitrogen purge for 24 hours to provide 992 gm, (89.9% yield). The resulting citrate monohydrate salt, polymorphic form was characterized via PLM, X-ray powder diffraction, proton NMR, Karl Fisher, DSC and elemental analysis. X-ray powder diffraction and PLM revealed it to be crystalline. The crystalline habit encountered were plates. The most intense reflections, d spacings, observed by X-ray powder diffraction were 13.280, 7.702, 7.446, 6.337, 5.332, 5.057, and 4.398 Å. The crystals exhibited a loss of water (volatilization) at 116° C. and a melt onset of 152.7 ° C. with decomposition. Hygroscopicity measurements demonstrated that 2.52% wt./wt. water was absorbed at 90% RH. Karl Fisher analysis showed the presence of 2.7% water (2.66% theoretical) verifying that the monohydrate was synthesized. Elemental analysis validated the purity of the salt synthesized.
Slurrying the anhydrous citrate in water yields the crystalline monohydrate that does not lose its water under drying conditions, e.g., at 45° C. in vacuo.
The effective dosage for the pharmaceutical composition of the citrate monohydrate depends on the intended route of administration, the indicator, the indication to be treated, and other factors such as age and weight of the subject. In the following dosage ranges, the terms “mg A” refers to milligrams of the monohydrate. A recommended range for oral dosing is 5-300 mgA/day, preferably 40-200 mgA/day more preferably 40-80 mgA/day, in single or divided doses. A recommended range for oral administration in oral forms such as pills or tablets is 2.5 mgA/day to 160 mgA/day and preferably 5-80 mgA/day. It can also be given by intravenous.
REFERENCES:
patent: 5939433 (1999-08-01), Ito et al.
Hesketh, P.J. et al. : Randomized phase II study of the Neurokinin 1 receptor antagonist CJ-11,974 in the control of Cisplatin-induced emesis. J. Clin. Oncol. vol. 17, pp. 338-343, Jan. 1999.*
Biles, J.A. : Crystallography. Part II. J. Pharm. Sci. vol. 51, pp. 601-617, Jul. 1962.
Castaldi Michael James
Quallich George Joseph
Wint Lewin Theophilus
Appleman Jolene W.
Aulakh Charanjit S.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Polymorphs of a crystalline azo-bicyclo (2,2,2)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphs of a crystalline azo-bicyclo (2,2,2)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of a crystalline azo-bicyclo (2,2,2)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2532255